Terbinafine (Lamisil) 250 mg Treatment Duration
For onychomycosis, treat with terbinafine 250 mg daily for 6 weeks for fingernail infections and 12-16 weeks for toenail infections. 1
Treatment Duration by Site
The British Association of Dermatologists guidelines provide clear, licensed dosing recommendations:
- Fingernail onychomycosis: 6 weeks of continuous daily therapy
- Toenail onychomycosis: 12-16 weeks of continuous daily therapy
These durations are based on the licensed indications and supported by robust clinical trial data demonstrating superior efficacy compared to other antifungal agents 1.
Post-Treatment Monitoring
Re-evaluate patients 3-6 months after treatment initiation. If disease persists at this follow-up, additional treatment should be given 1. This extended follow-up period is necessary because terbinafine persists in nail tissue for considerable time after plasma elimination, allowing continued antifungal activity.
Evidence Supporting 12-Week Duration for Toenails
A randomized duration-finding study directly compared 6,12, and 24-week treatment courses for toenail onychomycosis 2. At 48-week follow-up, cure rates were:
- 6 weeks: 40%
- 12 weeks: 71%
- 24 weeks: 79%
While 24 weeks showed marginally higher cure rates, 12 weeks represents the optimal balance between efficacy and treatment burden, which is why this duration became the standard licensed recommendation 2.
Why Continuous Dosing (Not Pulse Therapy)
Do not use intermittent or pulse dosing regimens with terbinafine. Two large identical trials involving 2,005 patients demonstrated that pulsed terbinafine (350 mg daily for 2 weeks on/2 weeks off for 3 cycles) was significantly less effective than continuous daily dosing, with complete cure rates approximately 6% lower 3. Continuous treatment remains the optimal therapy despite no safety advantages with pulsed dosing.
Important Clinical Caveats
Baseline Monitoring Requirements
Before initiating therapy, obtain baseline liver function tests and complete blood count in patients with:
- History of heavy alcohol consumption
- Hepatitis
- Hematological abnormalities
- Active or chronic liver disease (terbinafine is contraindicated in these patients) 1
Patient Warnings
Warn all patients about permanent taste disturbance, though this is very rare 1. This adverse effect can be permanent and represents a critical counseling point.
Drug Interactions
Terbinafine has minimal drug-drug interactions, with the only potentially significant interaction involving drugs metabolized by cytochrome P450 2D6 1. Avoid combining terbinafine with tamoxifen, as terbinafine's CYP2D6 inhibition reduces conversion to endoxifen, diminishing tamoxifen's efficacy 4.
Why Terbinafine is First-Line
Terbinafine demonstrates superior efficacy compared to itraconazole and other alternatives. The landmark L.I.ON. study showed complete cure rates of 55% with terbinafine versus 26% with itraconazole at 72 weeks, with significantly lower relapse rates (23% vs 53% mycological relapse) 1, 5. This superior long-term effectiveness, combined with better tolerability and fewer drug interactions, establishes terbinafine as first-line therapy for dermatophyte onychomycosis 1.